Fosamax, a bone-strengthening drug taken by millions of Americans to ward off osteoporosis, appears to nearly double the risk of a potentially serious heart problem in women, according to research by ...

I’m a 65-year-old, overweight white woman. I recently had a DEXA scan, and based on the results, my general physician prescribed Fosamax for osteopenia. The first dose created a horrible reaction two ...

Two recent reports have linked the osteoporosis drug alendronate (Fosamax) with rare but serious side effects. In a letter to the New England Journal of Medicine published Jan. 1, a Food and Drug ...

DEAR DR. ROACH: I’m a 65-year-old, overweight white woman. I recently had a DEXA scan, and based on the results, my general physician prescribed Fosamax for osteopenia. The first dose created a ...

DEAR DR. ROACH: My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly in ...

If you’re one of the 8 million American women with osteoporosis, your doctor has probably talked to you about treatment options to slow the disease’s progression and keep your bones in tip-top shape.

TRENTON, N.J.TRENTON, N.J. — Drugmaker Merck & Co. said it will challenge its first loss in a trial blaming its osteoporosis drug for destroying a patient’s jawbone after a federal jury on Friday ...

Merck & Co., already battered by Vioxx lawsuits, is preparing for a blizzard of litigation from patients claiming they were harmed by Fosamax, the company's hot-selling osteoporosis drug. The ...

NEW YORK (Reuters), Sep 3 - Jurors heard sharply different closing arguments on Wednesday in a trial over whether or not Merck & Co.'s Fosamax drug treatment for osteoporosis caused a Florida woman's ...

As new research emerges, public opinion of osteoporosis drugs may be at stake. Jan. 1, 2009— -- The end of 2008 was not kind to the osteoporosis drug Fosamax. The first blow to the medication ...

WILMINGTON - Merck & Co. (NYSE:MRK) has sued the U.S. unit of Teva Pharmaceuticals (Nasdaq:TEVA) in a fresh move to block the sale in the United States of generic versions of Merck's anti-osteoporosis ...